Fluoxetine for Migraine Prophylaxis: A Double‐Blind Trial

D'Amato, Cesare Colucci; Pizza, V.; Marmolo, Teresa; Giordano, E.; Alfano, V.; Nasta, Antonio

doi:10.1046/j.1526-4610.1999.3910716.x

Cited by 82 publications

(41 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…29 After the 6 months, pain index scores for the fluoxetine group decreased from 135 (baseline) to 41.3 (SD Ϯ 63.8; p ϭ 0.001). The placebo group pain index was 98 at baseline and 61.1 at 6 months (SD Ϯ 57.7; p ϭ 0.07); however, differences were noted between treatment groups for baseline measures.…”

mentioning

confidence: 91%

Evidence-based guideline update: Pharmacologic treatment for episodic migraine prevention in adults

et al. 2012

View full text Add to dashboard Cite

Objective: To provide updated evidence-based recommendations for the preventive treatment of migraine headache. The clinical question addressed was: What pharmacologic therapies are proven effective for migraine prevention? Methods:The authors analyzed published studies from June 1999 to May 2009 using a structured review process to classify the evidence relative to the efficacy of various medications available in the United States for migraine prevention. Results and Recommendations:The author panel reviewed 284 abstracts, which ultimately yielded 29 Class I or Class II articles that are reviewed herein. Divalproex sodium, sodium valproate, topiramate, metoprolol, propranolol, and timolol are effective for migraine prevention and should be offered to patients with migraine to reduce migraine attack frequency and severity (Level A). Frovatriptan is effective for prevention of menstrual migraine (Level A). Lamotrigine is ineffective for migraine prevention (Level A). Neurology Epidemiologic studies suggest approximately 38% of migraineurs need preventive therapy, but only 3%-13% currently use it.1 In 2000, the American Academy of Neurology (AAN) published guidelines for migraine prevention.2,3 Since then, new clinical studies have been published on the efficacy and safety of migraine preventive therapies. This guideline seeks to assess this new evidence to answer the following clinical question: For patients with migraine, which pharmacologic therapies are proven effective for prevention, as measured by reduced migraine attack frequency, reduced number of migraine days, or reduced attack severity? This article addresses the safety and efficacy of pharmacologic therapies for migraine prevention.Separate guidelines are available for botulinum toxin. 4 The 2008 guideline included a Level B recommendation that botulinum toxin was probably ineffective for treatment of episodic migraine. A new guideline is in development. An updated guideline on nonsteroidal anti-inflammatory drugs 5 and complementary alternative treatments has been approved for publication as a companion to this guideline. 5 DESCRIPTION OF THE ANALYTIC PROCESSThe AAN and the American Headache Society participated in the development process. An author panel of headache and methodologic experts was assembled to review the evidence. Computerized searches of the MEDLINE, PsycINFO, and CINAHL databases identified new studies (published in English). The search strategy used the MeSH term "headache" (exploded) and a published search strategy for identifying randomized controlled trials ( Appendices e-1-e-5, reference e1, and tables e-1 and e-2 are available on the Neurology Web site at www.neurology.org.

show abstract

mentioning

confidence: 91%

Evidence-based guideline update: Pharmacologic treatment for episodic migraine prevention in adults

et al. 2012

View full text Add to dashboard Cite

show abstract

“…[3][4][5][6] There is increasing evidence that use of angiotensin converting enzyme (ACE) inhibitors can substantially reduce the frequency and severity of migraine attacks. Quite recently, a controlled clinical trial demonstrated a clear improvement of migraine, in terms of headache duration and severity, during ACE inhibition therapy with lisinopril when compared to placebo.…”

Section: Introductionmentioning

confidence: 99%

Reduction in the therapeutic intensity of abortive migraine drug use during ACE inhibition therapy—a pilot study

Rahimtoola

Buurma

Tijssen

et al. 2003

Pharmacoepidemiology and Drug

View full text Add to dashboard Cite

SUMMARYIntroduction Since a few case reports have demonstrated some beneficial effects of angiotensin converting enzyme (ACE) inhibitors in migraine prevention, we were interested in studying the impact of ACE inhibitors and angiotensin II receptor antagonists (Ang II) on the consumption of specific abortive migraine drugs and, therefore, indirectly on the frequency of migraine attacks. Methods Data from a large prescription database involving 95 patients initiating a specific abortive migraine drug (ergotamine or a triptan) and subsequently treated with either an ACE inhibitor or angiotensin receptor antagonist (index group: ACE/Ang II) or diuretic (reference group) were analysed. The effects of ACE/Ang II inhibition as well as diuretic therapy on reducing the frequency of migraine attacks were assessed by measuring the mean consumption of abortive migraine drug use, in DDDs per month ('therapeutic intensity'), before, during and after ACE/Ang II or diuretic therapy. A 'therapeutic fluctuation intensity estimate' of abortive migraine drug use for all patients was likewise calculated. Results On an individual level, the therapeutic intensity (TI) fluctuation estimate, 'during' relative to 'before' ACE diuretic therapy, was significantly larger for the ACE/Ang II group (62% reduction) than for the diuretic group (24% reduction) ( p ¼ 0.02). For patients who continued abortive migraine drug use during and after ACE/Ang II or diuretic therapy, a significantly larger reduction in this estimate was observed during ACE/Ang II inhibition (68.9%) compared to during diuretic therapy (10.5% increase) ( p ¼ 0.004). The TI fluctuation estimate, after relative to 'during', had increased by 50.3% after ACE/Ang II inhibition and had reduced by 22.2% after diuretic treatment ( p ¼ 0.1). Conclusions A clear reduction in the TI of abortive migraine drug use during the use of ACE inhibitors as compared to diuretic treatment was observed. Our findings may indirectly support a positive effect of ACE/Ang II inhibition on the frequency and severity of migraine attacks, as observed in other studies and reports.

show abstract

“…Triptans, selective serotonin 5-HT1B/1D agonists, are very effective acute migraine drugs [93,94]. Although conflicting results have been reported about the use of SSRIs (selective serotonin reuptake inhibitors) in migraine prevention [95][96][97][98], trycyclic antidepressants such as amitriptyline are currently employed in migraine prophylaxis with evidence supporting their effectiveness for use [99,100]. Thus genes in the serotonergic system have been investigated as potential candidates to mediate susceptibility to migraine.…”

Section: Neurotransmitter Functionmentioning

confidence: 99%

The search for migraine genes: an overview of current knowledge

Colson

Fernandez

Lea

et al. 2006

Cell. Mol. Life Sci.

View full text Add to dashboard Cite

Migraine is a complex familial condition that imparts a significant burden on society. There is evidence for a role of genetic factors in migraine, and elucidating the genetic basis of this disabling condition remains the focus of much research. In this review we discuss results of genetic studies to date, from the discovery of the role of neural ion channel gene mutations in familial hemiplegic migraine (FHM) to linkage analyses and candidate gene studies in the more common forms of migraine. The success of FHM regarding discovery of genetic defects associated with the disorder remains elusive in common migraine, and causative genes have not yet been identified. Thus we suggest additional approaches for analysing the genetic basis of this disorder. The continuing search for migraine genes may aid in a greater understanding of the mechanisms that underlie the disorder and potentially lead to significant diagnostic and therapeutic applications.

show abstract

Fluoxetine for Migraine Prophylaxis: A Double‐Blind Trial

Abstract: Even if preliminary and to be confirmed, these data seem to support the use of fluoxetine in the treatment of migraine.

Cited by 82 publications

References 0 publications

Evidence-based guideline update: Pharmacologic treatment for episodic migraine prevention in adults

Evidence-based guideline update: Pharmacologic treatment for episodic migraine prevention in adults

Reduction in the therapeutic intensity of abortive migraine drug use during ACE inhibition therapy—a pilot study

The search for migraine genes: an overview of current knowledge

Contact Info

Product

Resources

About